5 terminated. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Terminated 5 |
| Phase 2 | 1 | Terminated 1 |
Follow Progesterone Receptor Negative: new trials by email Literature Review of Progesterone Receptor Negative trials Research Report on Progesterone Receptor Negative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted Ipilimumab, Nivolumab, Talimogene Laherparepvec - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 6 | 2019-07-10 | 2023-08-15 |
| Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Biomarker Analysis, Enzalutamide, Pharmacological Study - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 30 | 2015-06-01 | 2022-08-22 |
| Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 | Terminated | National Cancer Institute (NCI) | 4 | 2011-01-01 | 2015-08-27 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer Carboplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Terminated | National Cancer Institute (NCI) | 14 | 2010-12-01 | 2015-09-04 |
| RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacogenomic Study - Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Terminated | National Cancer Institute (NCI) | 13 | 2009-11-01 | 2015-04-15 |
Breast Neoplasms (4) · Triple Negative Breast Neoplasms (4) · Breast Carcinoma In Situ (1)
Breast Diseases (5) · Neoplasms (5) · Neoplasms by Site (5) · Skin Diseases (5) · Skin and Connective Tissue Diseases (5) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma in Situ (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (2) · Pharmacogenomic Testing (2) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · CTLA-4 Antigen (1) · Carboplatin (1) · HhAntag691 (1) · Ipilimumab (1) · Lapatinib (1) · MK 2206 (1) · Nivolumab (1) · Paclitaxel (1) · Taxes (1) · enzalutamide (1) · talimogene laherparepvec (1)
National Cancer Institute (NCI) (3) · Jonsson Comprehensive Cancer Center (1) · Vanderbilt-Ingram Cancer Center (1)
United States (5)
Patricia LoRusso (2) · Ewa Mrozek (1) · John A Glaspy (1) · Vandana Abramson, MD (1)
P30CA022453 (2), U01CA062487 (2), P30CA016058 (1), P30CA068485 (1), U01CA062490 (1), U01CA070095 (1), U01CA076576 (1)